Literature DB >> 27535625

Mixed Pituitary Gangliocytoma and Prolactinoma Resistant to the Cabergoline Treatment.

Shigetoshi Yano1, Takuichiro Hide2, Ken Uekawa3, Yumi Honda4, Yoshiki Mikami4, Jun-Ichi Kuratsu5.   

Abstract

BACKGROUND: A gangliocytoma rarely coexists with a pituitary adenoma in a sellar lesion. Herein, we describe our experience in treating a mixed gangliocytoma and prolactinoma of the pituitary gland. CASE DESCRIPTION: A 16-year-old male presented with severe headache and vomiting. Magnetic resonance imaging showed a large pituitary tumor with hydrocephalus. Because of the increased levels of serum prolactin (PRL), we treated the patient with cabergoline, which decreased the tumor size and improved the hydrocephalus. Six months after the treatment, the tumor began to increase in size, despite the normalization of the PRL level with cabergoline treatment. An endoscopic transsphenoidal resection was performed and the tumor was mostly removed. Microscopic examination of the resected tumor showed a mixture of prototypical pituitary adenoma cells and the proliferation of mature ganglion cells. Immunohistochemistry showed that the ganglion cells were positively stained for synaptophysin, NeuN, and PRL as shown in the adenomatous component. A few cells were immunostained with both PRL and NeuN, and a few cells were immunopositive for nestin, but not PRL or synaptophysin.
CONCLUSIONS: Our findings showed the existence of cells that are phenotypically intermediate between ganglion cells and adenoma cells, and the existence of stem cell-like cells, which support the hypothesis that adenoma cells can transform into ganglion cells or that both ganglion and adenoma cells derive from common stem cells. Furthermore, the ganglion cells seemed to grow rapidly and independently of dopamine, which is in contrast to prototypical prolactinoma cells.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cabergoline; Dopamine agonist; Gangliocytoma; Prolactinoma; Transsphenoidal surgery

Mesh:

Substances:

Year:  2016        PMID: 27535625     DOI: 10.1016/j.wneu.2016.08.011

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  3 in total

1.  Observation of Clinicopathologic Features of Pituitary Adenoma With Neuronal Differentiation.

Authors:  Limei Zheng; Xiaorong Yan; Chengcong Hu; Peng Zhang; Yupeng Chen; Qiaoyan Zheng; Liwen Hu; Mi Wang; Guoping Li; Ping Wu; Changzhen Jiang; Jing Tian; Sheng Zhang; Xingfu Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-15       Impact factor: 5.555

2.  A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

Authors:  Rakesh Mishra; Subhas K Konar; Adesh Shrivastava; Pradeep Chouksey; Sumit Raj; Amit Agrawal
Journal:  Indian J Endocrinol Metab       Date:  2022-02-17

3.  Unilateral hydrocephalus from a gangliocytoma-somatotrophinoma: first reported case.

Authors:  Simon Ryder; Jed Robusto; Thomas Robertson; Hamish Alexander; Emma L Duncan
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-07-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.